Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

YF-Vax

(Yellow Fever vaccine)

Phase 3Vaccine

This vaccine protects people from getting yellow fever, a serious disease spread by mosquitoes in tropical and subtropical parts of Africa and South America.[1] YF-Vax is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]

YF-Vax is one of 69 biologic programs targeting Rheumatic Disease. It is currently in Phase 3.

3

Indications

26

Total Trials

8

Active Trials

68

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

ChickenpoxActive, not recruiting

Yellow FeverCompleted

Rheumatic DiseasePreclinical

Active, not recruiting

ChickenpoxPreclinical

Active, not recruiting

Yellow FeverPhase 3

Completed

Competition

Competitive Landscape

63 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Voltaren

Aleve

Jazz Pharmaceuticals

Anjeso

Boehringer Ingelheim

Indocin

CCosette Pharmaceuticals, Inc.

Advil

Decadron

AAspen Global Incorporated

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ansaid

PPharmacia and Upjohn

Bextra

TThe Searle Company Limited Pakistan

Oruvail

WWyeth-Lederle Vaccines

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Yellow Fever

NCT05011123

Phase 2Active, not recruiting

Yellow Fever

NCT04942210

Q4 2027

Phase 2Active, not recruiting

Malaria Vaccine

NCT06879327

Post-ApprovalActive, not recruiting

Yellow Fever

NCT02555072

Q4 2028

ApprovedRecruiting

Vaccine Response Impaired

NCT06148025

Q1 2030

Phase 3Recruiting

Yellow Fever

NCT07103148

Clinical

Trials by Indication[1]

Yellow Fever9 trials

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

Completed·SSri Edupuganti·Phase 4·NCT01290055·27 enrolled

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Completed· Sanofi logo

Sanofi·Phase 3·NCT01436396·792 enrolled

Yellow Fever Human Infection Model With YF-17D

Unknown status·LLeiden University Medical Center·N/A·NCT05901454·30 enrolled

Show 6 more trials

Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)

Active, not recruiting·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT02555072·4,761 enrolled

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

Completed· Sanofi logo

Sanofi·Phase 1·NCT04142086·73 enrolled

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05011123·690 enrolled

Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months

Not yet recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 3·NCT06815835·1,530 enrolled

A Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of Age

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07103148·2,440 enrolled

Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT04942210·568 enrolled

Immunogenicity2 trials

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Completed· Novartis logo

Novartis·Phase 3·NCT01466387·552 enrolled

Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine

Completed·—·Phase 4·NCT05374317·88 enrolled

Hepatitis B1 trial

Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

Completed· GSK logo

GSK·Phase 3·NCT01345240·705 enrolled

Rotavirus Vaccine1 trial

Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali

Completed·PPATH·Phase 4·NCT02286895·600 enrolled

Rheumatic Disease1 trial

Yellow Fever Vaccine in Patients With Rheumatic Diseases

Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT03430388·600 enrolled

12 more indications

Vaccination1 trial

The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans

Completed·SSingapore General Hospital·Phase 2·NCT01943305·84 enrolled

Chickenpox1 trial

Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines

Completed·UUniversity of Surrey·N/A·NCT01765413·48 enrolled

Immune Response1 trial

Human Immune Responses to Yellow Fever Vaccination

Completed·EEmory University·Phase 4·NCT00694655·239 enrolled

Inflammation1 trial

The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

Completed·UUniversity of Minnesota·Phase 1/2·NCT04269265·43 enrolled

Toxicity1 trial

Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination

Active, not recruiting·UUniversity of Aarhus·Phase 4·NCT04083430·60 enrolled

Double-blind1 trial

Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

Completed· Sanofi logo

Sanofi·Phase 3·NCT07002060·640 enrolled

MMR Vaccine1 trial

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months

Completed·SShanghai Institute Of Biological Products·Phase 3·NCT06399003·1,200 enrolled

Adult1 trial

Phase 3 Single Arm, Open Study on vYF in Adults

Completed· Sanofi logo

Sanofi·Phase 3·NCT07222059·254 enrolled

Malaria Vaccine1 trial

A Phase 2b Multicenter Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of R21/Matrix-M Malaria Vaccine in African Infants With Different Immunization Schedules

Active, not recruiting·PPATH·Phase 2·NCT06879327·975 enrolled

Infections1 trial

A Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in Africa

Completed· GSK logo

GSK·Phase 2·NCT06213506·180 enrolled

Vaccine Response Impaired1 trial

A Human Experimental Medicine Study to Assess Whether the Gut Microbiota Regulates Specific and Non-specific Immune Responses to Vaccination

Recruiting·SSouth Australian Health and Medical Research Institute·Approved·NCT06148025·348 enrolled

Unspecified1 trial

Single Cell Transcriptomics for Characterizing the Human Immune Response to Yellow Fever Vaccination

Completed·RRockefeller University··NCT03458780·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Yellow Fever vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yellow Fever vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yellow Fever vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Related News